£520.00

It has never been this cheap. We have no record of a lower price.

£520 today · cheaper than every other day in the last 3 months

Alpha-1 Antitrypsin Deficiency Treatment Outlook 2023-2028

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 24 days · 24 data points (no recent data)

Historical
Generating forecast…
£520.00 £494.00 £504.40 £514.80 £525.20 £535.60 £546.00 11 August 2026 16 August 2026 22 August 2026 28 August 2026 03 September 2026
View at Amazon ↗

Price data last checked 67 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 24 days • 1 price levels

Days at Price
24 days 0 6 12 18 24 £520 Days at Price

Price Analysis

Most common price: £520 (24 days, 100.0%)

Price range: £520 - £520

Price levels: 1 different prices over 24 days

Description

This comprehensive study provides a detailed outlook for alpha-1 antitrypsin deficiency treatment augmentation therapies in the United States from 2023 to 2028. The report focuses on latent demand, providing potential industry earnings (P.I.E.) estimates in millions of U.S. dollars across approximately 12,600 cities. By analyzing data at the city and state levels, the study offers comparative benchmarks that show the percent share each city holds relative to its state and the entire country. This statistical approach provides actionable data for distribution and sales professionals looking to gauge market potential and optimize their strategies within the United States.

Key Features

Provides latent demand outlook for alpha-1 antitrypsin deficiency treatment augmentation therapies in the United States.

Includes potential industry earnings (P.I.E.) estimates in millions of U.S. dollars for approximately 12,600 cities.

Reports the percent share of each city relative to its state and the total United States market.

Offers comparative benchmarks to help readers gauge market value for specific cities against others.

Delivers a statistical approach designed to assist with distribution and sales planning.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
26 October 2022
Listed Since
09 November 2022

Similar Products You Might Like

Alpha-1 Antitrypsin Deficiency Treatment Outlook in India
99% match

Alpha-1 Antitrypsin Deficiency Treatment Outlook in India

£515.00 03 Sep 2026
Alpha-1 Antitrypsin Deficiency Treatment Outlook 2023-2028
99% match

Alpha-1 Antitrypsin Deficiency Treatment Outlook 2023-2028

£520.00 02 Sep 2026
Alpha-1 Antitrypsin Deficiency Treatment Outlook in India
99% match

Alpha-1 Antitrypsin Deficiency Treatment Outlook in India

£515.00 02 Sep 2026
World Outlook: Alpha-1 Antitrypsin Deficiency Treatments
99% match

World Outlook: Alpha-1 Antitrypsin Deficiency Treatments

£790.00 28 Aug 2026
The 2026-2031 World Outlook for Alpha-1 Antitrypsin Deficiency Treatments
99% match

The 2026-2031 World Outlook for Alpha-1 Antitrypsin Deficiency Treatments

£885.00 27 Aug 2026
The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies in China
99% match

The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies in China

£495.00 30 Sep 2026
The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies in Japan
99% match

The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies in Japan

£495.00 07 Nov 2026
The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies for US Zip Codes
98% match

The 2023-2028 Outlook for Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies for US Zip Codes

£490.00 01 Oct 2026
Alpha-1 Antitrypsin Deficiency Treatment Outlook 2023-2028
98% match

Alpha-1 Antitrypsin Deficiency Treatment Outlook 2023-2028

£490.00 24 Aug 2026
Alpha-1 Antitrypsin Drug Outlook 2023-2028 US Zip Codes
98% match

Alpha-1 Antitrypsin Drug Outlook 2023-2028 US Zip Codes

£490.00 26 Aug 2026
US Air Treatment Products Outlook 2023-2028 Study
97% match

US Air Treatment Products Outlook 2023-2028 Study

£520.00 24 Aug 2026
Anti-Inflammatory Asthma Drugs Outlook 2023-2028 Report
96% match

Anti-Inflammatory Asthma Drugs Outlook 2023-2028 Report

£520.00 03 Sep 2026
US Animal Health API Outlook 2023-2028 Report
96% match

US Animal Health API Outlook 2023-2028 Report

£520.00 03 Sep 2026
Pulmonary Fibrosis Treatment Outlook 2023-2028 - US Study
96% match

Pulmonary Fibrosis Treatment Outlook 2023-2028 - US Study

£520.00 05 Nov 2026
The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in India
96% match

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in India

£515.00 02 Sep 2026
2023-2028 US Advanced Therapy Medicinal Products Outlook
96% match

2023-2028 US Advanced Therapy Medicinal Products Outlook

£520.00 05 Nov 2026
The 2023-2028 World Outlook for Air Treatment Products
96% match

The 2023-2028 World Outlook for Air Treatment Products

£795.00 05 Nov 2026
The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in India
96% match

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in India

£515.00 02 Sep 2026
Advanced Therapy Medicinal Products Outlook India 2023-2028
96% match

Advanced Therapy Medicinal Products Outlook India 2023-2028

£515.00 06 Nov 2026
World Outlook for Idiopathic Pulmonary Fibrosis Treatments
96% match

World Outlook for Idiopathic Pulmonary Fibrosis Treatments

£790.00 05 Nov 2026
The 2023-2028 Outlook for Non-Small Cell Lung Cancers in the United States
96% match

The 2023-2028 Outlook for Non-Small Cell Lung Cancers in the United States

£520.00 02 Oct 2026
The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States
96% match

The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States

£520.00 30 Sep 2026
The 2023 Report on Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies: World Market Segmentation by City
96% match

The 2023 Report on Alpha-1 Antitrypsin Deficiency Treatment Augmentation Therapies: World Market Segmentation by City

£795.00 01 Sep 2026
The 2023-2028 Outlook for Non-Small Cell Lung Cancers in India
96% match

The 2023-2028 Outlook for Non-Small Cell Lung Cancers in India

£515.00 01 Oct 2026